Weight-adjusted aspirin for cardiovascular prevention
Understanding the sources of variability in patients' responses to medicines has the potential to improve efficacy and safety through personalisation of treatment. Individual factors-ie, a patient's risk of cardiovascular events-are already considered when deciding who is prescribed low-dose aspirin for cardio vascular prevention. However, aspirin inhibits just one of several pathways of platelet activation, so it is not surprising that many patients still exper ience cardiovascular events.
1 Factors that potentially contribute to these treatment failures, sometimes named as aspirin resistance, have been studied ex ten sively, and several plausible mechanisms have been suggested, including non-adherence, 2 accelerated platelet turnover in patients with diabetes, 3 drug interactions with non-steroidal anti-inflammatory drugs, 4 reduced bioavailability due to enteric coating, 5, 6 and bodyweight. 7 Considering these factors when tailoring dose, dosing frequency, and perhaps even time of dosing to individual patients might have substantial public health effects.
In The Lancet, Peter Rothwell and colleagues 8 report their investigation of the effects of the interaction between bodyweight and aspirin dose on the risk of vascular events, bleeding, and cancer by combining individual patient data from randomised controlled trials. Their analysis included nine trials of aspirin in primary prevention of cardiovascular events and major bleeding (including roughly 103 000 patients) and four of aspirin in secondary prevention of stroke (including roughly 13 000 patients). The authors found that lowdose aspirin (≤100 mg/day) prevented cardiovascular events only in individuals with low bodyweight (<70 kg), whereas higher doses of aspirin (≥300 mg/day) were effective only in individuals weighing 70 kg or more. A similar interaction was observed for colorectal cancer and bleeding, albeit with an apparently higher weight cutoff (≥80 kg for colorectal cancer and ≥90 kg for major bleeds). Notably, the analysis implies that weightadjusted aspirin dosing might substantially improve the effectiveness of aspirin. Low-dose aspirin reduced cardiovascular events by 23% (hazard ratio [HR] 0·77, 95% CI 0·68-0·87; p<0·0001) in individuals weighing less than 70 kg, compared with a reduction of only 12% (0·88, 0·81-0·95; p=0·0008) in the overall primary prevention population when weight was not considered. Also, the authors suggest that sex differences in bodyweight-eg, more men than women weighed more than 70 kgmight explain aspirin's long recognised lack of efficacy in preventing stroke in men. The difference in stroke risk between men and women was no longer detectable when bodyweight was accounted for.
Weight can affect drug distribution and clearance, and is known to modulate platelet inhibition by clopidogrel and prasugrel. 9, 10 Moreover, weight-adjusted dosing is common for intravenous platelet inhibitors (glycoprotein IIb/IIIa antagonists and cangrelor). With regard to aspirin, extensive clearance by esterases in the intestine, plasma, blood cells, and the liver results in a systemic bioavailability of just 50%. It seems plausible that individuals with a larger body mass would have a greater quantity of these esterases than would smaller individuals, resulting in reduced aspirin bioavailability. This hypothesis is supported by the observation that the interaction between weight and risk of cardiovascular events was accentuated with enteric-coated aspirin, which has about 40% lower systemic bioavailability than does non-coated aspirin.
11
The purpose of using low doses of aspirin is to limit systemic aspirin exposure and the consequent depression of homoeostatic cyclo-oxygenase (COX) products in vasculature and the stomach. Aspirin irreversibly acetylates COX-1 in platelets that are unable to synthesise new enzyme. Thus, low doses of aspirin can inhibit platelet function as long as more platelets are inhibited than are newly released from megakaryocytes. This inhibition can occur presystemically before inactivation by liver esterases. 12 Prostacyclin, the vascular COX product intended to be spared by use of low doses of aspirin, is a potent platelet inhibitor and a central molecule in the important negative feedback mechanism that limits the growth of thrombi at sites of vascular injury. 13 The apparent lack of efficacy of intermediate-dose and high-dose aspirin in individuals weighing less than 70 kg raises the question of whether these treatment failures might reflect inhibition of vascular prostacyclin because of the increased systemic bioavailability of aspirin in this subgroup.
How might weight-adjusted dosing of aspirin affect bleeding risk? In the trials included in the analysis, 80% of men and nearly 50% of women weighed 70 kg or more.
